Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).

Annamaria BrioliKirsi ManzMarkus PfirrmannMathias HänelAndreas Christoph SchwarzerGabriele Prange-KrexChristian FabischStefan KnopThomas IllmerBeate Krammer-SteinerAndreas HochhausMarie von Lilienfeld-ToalLars-Olof Mügge

Published in: Journal of cancer research and clinical oncology (2019)

A frailty assessment with appropriate dose modification for induction therapy should be mandatory for all elderly non-transplant-eligible myeloma patients.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
community dwelling
stem cells
middle aged
patient reported outcomes
bone marrow